검색어: expanded disability status scale (영어 - 몰타어)

edss: expanded disability status scale gd+: gadolinium-enhancing
edss: expanded disability status scale gd+: li jtejbu gadolinium

at entry, patients had an expanded disability status scale (edss) score ≤5.5.
meta ddaħħlu fl-istudju, il-pazjenti kellhom punteġġ ta' ≤5.5 fuq l-iskala tal-istat ta' diżabilità mkabbra (edss).

disability progression was measured as an increase in the expanded disability status scale (edss) of 1.0 point, sustained for at least six months.
kienet ikkunsidrata bħala deterjorazzjoni fid- diżabilita 'żieda ta' punt fl- edss (expanded disabilty status scale) li baqgħet għal ta ’ l- inqas sitt xhur.

efficacy (see table below) and safety were demonstrated in subjects with expanded disability status scale (edss) scores ranging from 0 to 5 inclusive, who had experienced at least
l-effikaċja (ara t-tabella hawn taħt) u s-sigurtà ntwerew f’individwi b’punteġġi tal-expanded disability status scale (edss) li jvarjaw minn 0 sa 5 inklużivi, li kellhom mill-inqas 1 rikaduta matul is-sena qabel ma ntgħażlu b’mod każwali, jew, fi żmien

effectiveness was measured based on the number of relapses, and the changes in the patients’ level of disability measured using a standard scale (the expanded disability status scale).
l-effikaċja tkejlet abbażi tan-numru ta’ attakki reċidivi, u l-bidliet fil-livell tad-diżabbiltà tal- pazjent, imkejla bl-użu ta’ skala standard (expanded disability status scale).

the main measures of effectiveness were the number of relapses, and the changes in the patients’ level of disability, measured using a standard scale (the expanded disability status scale).
il- kejl ewlieni tal- effika ja kienet in- numru ta ’ rikaduti, u l- bidliet fil- livell tad- di abilità tal- pazjent, imkejla permezz tal- u u ta ’ skala standard (expanded disability status scale).

expanded disability status score (edss) was between 0 and 5.5. a third study targeting the same patient population was completed after registration of gilenya.
l-iskala mwessgħa tal-istat ta’ diżabbiltà (edss) kienet bejn 0 u 5.5. it-tielet studju li mmira l-istess popolazzjoni ta’ pazjenti tlesta wara r-reġistrazzjoni ta’ gilenya.

time to onset of sad was defined as an increase of at least 1 point on the expanded disability status scale (edss) from a baseline edss score ≥ 1.0 (1.5 point increase for patients with baseline edss of 0) that was sustained for 6 months.
Żmien sal-bidu ta' sad ġie definit bħala żieda ta' mill-inqas punt wieħed fuq l-iskala tal-istat ta' diżabilità mkabbra (edss) minn punteġġ edss fil-linja bażi ta' ≥ 1.0 (żieda ta' 1.5 punti għal pazjenti b'edss fil-linja bażi ta' 0) li kienet sostnuta għal 6 xhur.

if the patient fails to respond, for example a steady progression in expanded disability status scale (edss) for 6 months occurs or treatment with at least 3 courses of adrenocorticotropic hormone (acth) or corticosteroids during a one-year period is required despite extavia therapy, treatment with extavia should be stopped.
jekk il- pazjent ma jirrispondix għall- kura, per eżempju jekk ikun hemm progress regolari fl- iskala mwessa ’ ta ’ l- istat ta ’ diżabilità (edss) għal 6 xhur jew ikun hemm il- htieġa ta ’ kura b’ ta ’ l- anqas 3 korsijiet ta ’ ormon adrenokortikotropiku (acth) jew kortikosterojdi tul perijodu ta ’ sena minnkejja l- użu ta ’ extavia, il- kura b’ extavia għandha titwaqqaf.

the performance status scale, for head and neck (pss-hn) subscales designed to measure understandability of speech, ability to eat in public, and normalcy of diet, was significantly in favor of tpf as compared to pf.
l-iskaletti tal-iskala tal-istatus ta’ kapaċità, għar-ras u l-għonq (pss-hn), maħduma biex jitkejlu l-ftehim fid-diskors, il-kapaċità biex wieħed jiekol fil-publiku, u jsegwi dieta normali, kienu b’mod sinifikattiv favur tpf meta mqabbel ma’ pf.

clinical benefit parameters the performance status scale, for head and neck (pss-hn) subscales designed to measure understandability of speech, ability to eat in public, and normalcy of diet, was significantly in favor of tpf as compared to pf.
32 il- parametri tal- benefiċċju kliniku l- iskaletti ta ’ l- iskala ta ’ l- istatus ta ’ kapaċità, għar- ras u l- għonq (pss- hn), maħduma biex jitkejlu l - ftehim fid- diskors, il- kapaċità biex wieħed jiekol fil- publiku, u jsegwi dieta normali, kienu b’ mod sinifikattiv favur tpf meta mqabbel ma ’ pf.

efficacy as monotherapy has been evaluated in one randomised, double-blind, placebo-controlled study lasting 2 years (affirm study) in relapsing-remitting ms patients who had experienced at least 1 clinical relapse during the year prior to entry and had a kurtzke expanded disability status scale (edss) score between 0 and 5.
l-effikaċja bħala monoterapija kienet evalwata fi studju randomised, double-blind, kkontrollat bil-plaċebo u li dam sentejn (studju affirm) f’pazjenti b’ms li tirkada u tbatti li esperjenzaw minn ta’ l-inqas episodju wieħed ta’ rkadar waqt is-sena ta’ qabel ma daħlu u kellhom punteġġ kurtzke expanded disability status scale (edss) ta’ bejn 0 u 5.